.avif)
.avif)
.avif)
Alnylam Pharmaceuticals Email Format
Biotechnology Research
・
1,001-2,500 employees
・
Cambridge, MA, USA
Alnylam Pharmaceuticals is a leading biopharmaceutical company pioneering RNA interference therapeutics to treat rare and prevalent diseases worldwide.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@alnylam.com
Company Overview
Industry
Biotechnology Research
Founded
2002
Headquarters
Cambridge, MA, USA
Revenue
$1B-$2.5B
FUNDING Stage
Public
Website
Key Executives
Yvonne Greenstreet (Chief Executive Officer), Jeff Poulton (Executive Vice President and Chief Financial Officer), Vasant Jadhav (Chief Technology Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals uses the firstinitiallast format on alnylam.com, so Jane Smith would be jsmith@alnylam.com.
What approved RNAi therapeutics does Alnylam Pharmaceuticals currently market in the United States?
Alnylam Pharmaceuticals has four approved products in the US: AMVUTTRA (vutrisiran) and ONPATTRO (patisiran) for transthyretin amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.
How is Alnylam Pharmaceuticals co-developing zilebesiran for hypertension?
Alnylam Pharmaceuticals partnered with Roche in 2023 to co-develop and co-commercialize zilebesiran, an investigational RNAi therapeutic for hypertension. The companies advanced it into the global Phase 3 ZENITH cardiovascular outcomes trial, with the first patient dosed in October 2025.
Where does Alnylam Pharmaceuticals have offices outside of its Cambridge, Massachusetts headquarters?
Beyond Cambridge, Alnylam Pharmaceuticals maintains European business offices in Maidenhead, UK and Zug, Switzerland, satellite offices across Munich, Amsterdam, Vienna, Paris, Milan, Madrid, and Stockholm, and additional offices in Tokyo, Sao Paulo, and Mississauga, Canada.
Who leads Alnylam Pharmaceuticals as CEO, and what is her background?
Yvonne Greenstreet has served as CEO of Alnylam Pharmaceuticals since January 2022. She holds a medical degree from the University of Leeds and an MBA from INSEAD, and previously served the company as President and Chief Operating Officer beginning in 2020. If you need to verify her contact details, Clay can help enrich that information.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating